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Objectives: In patients with burns an early accurate diagnosis of burn depth is 
essential to determine optimal treatment. The combination of Laser Doppler imaging 
(LDI) and clinical assessment leads to an accurate estimate of burn depth. However, 
the actual effects of the introduction of LDI on therapeutic decisions, clinical out-
comes and costs are unknown. The aim of our study was to analyse the effectiveness 
and cost-effectiveness of LDI in burn care. The effects of LDI on decision-making, 
clinical outcomes, costs, and cost-effectiveness were assessed. MethOds: A ran-
domised controlled trial was conducted in all three Dutch burn centres, includ-
ing subsequent patients with burns of indeterminate depth. In the standard care 
(SC) group, burn depth and treatment choices were based on clinical assessment 
only, in the other group (LDI) clinical assessment and LDI results were combined. 
Primary outcome was the effect of the introduction of LDI on wound healing time. 
The economic evaluation was performed from a societal perspective with a bottom 
up approach, following the micro-costing method. Results: Mean time to wound 
healing from randomisation was 14.3 days in the LDI group and 15.5 days in the SC 
group (p= 0.258). In the subgroup of clinical patients requiring surgery earlier deci-
sion for surgery and a shorter wound healing time were observed in the LDI group 
(16.0 versus 19.9 days, p= 0.029). Mean total costs per patient were € 18 549 versus 
€ 18 896 (p= 0.837). cOnclusiOns: LDI proved to provide guidance for therapeutic 
decisions with a significantly shorter wound healing time in the subgroup of clinical 
patients requiring surgery. When time to surgery can be reduced by 2.4 days, similar 
to the time to decision for surgery in our study, cost savings of € 794 per scanned 
patient can be achieved.
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Objectives: Actinic Keratosis (AK) is the most common neoplastic lesion of the 
skin, its prevalence in Italy is 1.4% in the adult population, over the age of 45 
years. The objective of this study is to evaluate through the development of a 
decision-tree model, the impact in terms of cost-effectiveness of treatment of 
patients with actinic keratosis (on the face), of ingenolo mebutato gel vs. imiqui-
mod cream. MethOds: The effectiveness was expressed in terms of utility; the 
ratio of cost effectiveness was expressed in terms of cost per Quality Adjusted Life 
Years (QALYs). The time horizon of the simulation was 12 months. For ingenolo 
mebutato was considered the price to the public starting from the ex-factory price 
currently lower in Europe (Spain price), while for imiquimod has been adopted 
the reference price, because of the drug generication. It was also considered the 
adherence rate of patients to the two treatment alternatives, due to the different 
duration of treatment (2-3 days Vs. 4-8 weeks) and adverse events, which in the 
case of imiquimod may persist for all the therapy lenght. Results: Based on 
these assumptions, ingenolo mebutato therapy is found to be less expensive and 
more effective, and so dominant, compared to imiquimod. The cost-effectiveness 
analysis has been tested with univariate sensitivity analysis, which confirmed 
the validity of the base case. cOnclusiOns: Based on these statement, it seems 
clear that ingenolo mebutato, due to its way of administration combined with its 
expected cost, represents a rational investment for the treatment of AK in the 
landscape of our national health system.
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Objectives: The national immunization program (NIP) on a voluntary basis 
started in 2010 in Croatia, including the 10-valent PCV10 and the 13-valent PCV13. 
We compare the cost-effectiveness of PCV10 and PCV13 use in the NIP. MethOds: 
A Markov model was developed to examine cost-effectiveness of PCV13 versus 
PCV10 from the payer’s perspective in 10 years. The simulated diseases were inva-
sive pneumococcal disease (bacteremia and meningitis), all-cause community 
acquired pneumonia (CAP), and all-cause acute otitis media (AOM). Direct effec-
tiveness was extrapolated from PCV7 clinical trials, adjusted by local serotype. 
Indirect effect (IE) was extrapolated from the US surveillance data following uni-
versal PCV7 use. Vaccine prices per dose for PCV10 and PCV13 were € 45.16 and 
€ 47.71, respectively. The epidemiology inputs were based on national sources or 
adopted from neighboring Slovenia. Costs were obtained from local reimburse-
ment lists and the DRG system. The IE for PCV10 was separately taken at 0%, 
50% and 100% level. Results: Compared to PCV10 with presumed no IE, PCV13 
could avoid additional 985 IPD cases, 15583 cases of inpatient and 26481 cases of 
outpatient CAP, and 53555 AOM cases, whereas for modeled 50% IE of PCV10 only 
679,10568,17 641 and 35026 cases would be avoided, and for modeled 100% IE of 
PCV10 372,5552,8798,16498 cases would be avoided, respectively. There would be 
2778 or 1958 or, 1137 deaths avoided, respectively. PCV13 compared to PCV10 with 
assumed no IE leads to € 3.060 million more spent on vaccination and € 28.585 mil-
lion saved, giving thus overall saving € 25.524 million in 10 years. cOnclusiOns: 
The cost-effectiveness analysis showed PCV10 to be dominated by PCV13 by its 
overall lower costs and higher number of QALY as well as LYG gained, regard-
less of the IE level. The results were most sensitive to the cost and incidence of 
hospitalized pneumonia.
characteristics were obtained from WHO estimates or local sources, adjusted to 
local conditions. PCV13 direct and indirect effectiveness was extrapolated from 
PCV7 trials and surveillance records, adjusted to local serotype distribution. Cost 
of vaccine was USD 16.34. A discount rate for cost and life-years was 3%. The payer 
and societal perspectives were considered. Results: The budget impact in a sin-
gle year with PCV13-based NIP in place would amount to USD 1.82 million, or USD 
7.93 million without indirect vaccine protection considered. From this investment, 
141 971 illnesses (1071 IPDs, 12477 CAPs and 128423 OMs) and 347 deaths could be 
avoided annually. Without indirect vaccine protection, 58 524 illnesses (601 IPD, 4721 
CAP, 53202 OM) and 184 deaths could be avoided. The cost-effectiveness analysis 
produced ICER of USD 340/LYG or USD 367/QALY from the payer’s perspective. From 
the societal perspective, the NIP is dominant. Not considering indirect protection, 
the ICER would be USD 140/LYG or USD 152/QALY from a societal perspective and 
USD 1157/LYG or USD 1254/QALY from a payer perspective. cOnclusiOns: PCV13-
based NIP delivers benefits and cost savings that greatly offset the investment into 
vaccine. WHO strongly encourages investment in interventions that deliver an addi-
tional year of life in full quality for less than one GDP per capita (USD 4237); hence, 
a PCV13-based NIP with the above ICER presents an attractive option.
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Objectives: Ranibizumab has demonstrated efficacy in patients with myopic 
choroidal neovascularization (mCNV) and is the first anti-VEGF licensed in this 
indication. Aflibercept is being evaluated for use in mCNV. An existing model dem-
onstrating the cost-effectiveness of ranibizumab versus verteporfin photodynamic 
therapy was adapted to provide an initial evaluation of ranibizumab versus afliber-
cept. MethOds: A Markov model in mCNV with a lifetime horizon and visual acuity 
health states was adapted to evaluate the cost-effectiveness of ranibizumab and 
aflibercept from a UK health care perspective. Baseline characteristics, injection 
frequency and ranibizumab efficacy were based on the disease activity treatment 
arm from the RADIANCE study (n= 116, Caucasian, Indian and East Asian patients). 
Data for aflibercept were derived from initial results for the aflibercept treatment 
arm from the MYRROR study (n= 90, East Asian patients only). Relative efficacy 
was assessed by indirect comparison. An evaluation using the East Asian subgroup 
of the ranibizumab disease activity treatment arm in RADIANCE (n= 35) was also 
conducted. Results: Ranibizumab dominated aflibercept in both evaluations. 
Based on the disease activity arm from RADIANCE, ranibizumab was associated 
with a lower lifetime cost (incremental cost -£1770) and higher lifetime quality-
adjusted life-years (QALYs) (incremental gain 0.02) than aflibercept. Results were 
similar for the evaluation based on the East Asian subgroup. Ranibizumab was 
associated with a lower lifetime cost (incremental cost -£2856) and higher lifetime 
QALYs (incremental gain 0.06) than aflibercept. These results were driven by the 
greater number of injections, higher treatment and recurrence costs, and smaller 
proportion of patients gaining ≥ 20 letters visual acuity for aflibercept compared 
with ranibizumab. cOnclusiOns: This initial analysis suggests that ranibizumab 
is less costly and is associated with a gain in QALYs relative to aflibercept based on 
the disease activity arm and the East Asian subgroup from RADIANCE, as well as 
initial data from MYRROR.
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Objectives: Central retinal vein occlusion (CRVO) is caused by a blood clot in the 
central retinal vein, which slows or stops blood from leaving the retina. As a result, 
blood and fluids can accumulate, causing retinal injury and vision loss. Thus, a 
major complication in eyes with CRVO is macular oedema (ME) and is the primary 
factor for poor visual acuity and visual fields in non-ischemic CRVO. A global cost-
effectiveness model was developed and adopted to estimate effects and associ-
ated costs, in Sweden, for treatment of ME secondary to CRVO with aflibercept 
compared to ranibizumab. MethOds: A Markov model was developed, including 
health states that reflect the clinical treatment and disease progression/regression 
of the ME. The simulated patient population consisted of adults treated for ME 
secondary to CRVO with an average starting-age of 64 years. Patients were treated 
and monitored for two years and followed for 15 years in the base case. Treatment 
regimens were taken from clinical trials with aflibercept (GALILEO & COPERNICUS) 
and ranibizumab (CRUISE & HORIZON), with 8.2 vs. 8.8 injections the first year and 
2.9 vs. 3.5 injections the second year, respectively. Results: Aflibercept can be 
regarded as a cost-effective, i. e. dominating, treatment-alternative compared to 
ranibizumab as aflibercept is both less costly (total incremental cost of more than 
-35,000 SEK) and more effective (total incremental QALYs of 0.061) than ranibi-
zumab. Due to the more treatments, ranibizumab had higher drug (incremental 
cost: -8,537 SEK) and administration (incremental cost: -5,793 SEK) costs compared 
to aflibercept. Probabilistic sensitivity analysis showed that aflibercept was domi-
nating over ranibizumab in 70% of the simulations. cOnclusiOns: Aflibercept 
is more cost-effective than ranibizumab for the treatment of ME secondary to 
CRVO in Sweden.
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